Comparative Pharmacology
Head-to-head clinical analysis: METRONIDAZOLE IN PLASTIC CONTAINER versus VANDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRONIDAZOLE IN PLASTIC CONTAINER versus VANDAZOLE.
METRONIDAZOLE IN PLASTIC CONTAINER vs VANDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
After intracellular reduction, metronidazole and its metabolites interact with DNA leading to inhibition of nucleic acid synthesis and cell death. It is active against anaerobic bacteria and protozoa.
VANDAZOLE is a nitroimidazole antimicrobial agent that undergoes reduction by bacterial nitroreductases, forming cytotoxic free radicals that damage DNA and inhibit nucleic acid synthesis.
500 mg IV every 8 hours or 7.5 mg/kg IV every 6 hours (loading dose 15 mg/kg) for most anaerobic infections.
2 g orally as a single dose once daily for 2 days.
None Documented
None Documented
8 hours (range 6-12 hours) in adults with normal hepatic function; prolonged to 15-30 hours in severe liver disease
Approximately 8-10 hours in adults; prolonged to 20-25 hours in hepatic impairment.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (<5%)
Primarily renal (40-70% unchanged), with biliary/fecal elimination accounting for 15-20% as metabolites.
Category A/B
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic